MAPT and Alzheimer disease: In recent years, immunotherapies targeting the tau protein have advanced from proof-of-concept animal studies to clinical trials.1–6 Currently, there are ten antibodies and two tau immunogens being examined in phase 1–3 trials in patients with AD or in healthy subjects.